A
Anjarium Biosciences AG
Biotech & Life Sciences · Zurich, Switzerland · Founded 2017
Anjarium Biosciences is a transforming exosomes from cellular message couriers to potent therapeutic carriers for debilitating diseases MoreLess
Anjarium Biosciences, headquartered in Switzerland, specializes in advanced synthetic DNA technology designed to enhance mRNA production and gene therapy. The company serves researchers and manufacturers in the life sciences sector, providing customizable DNA constructs that accelerate the discovery and delivery of genetic medicines. Operating in the biotechnology market, Anjarium's business model focuses on delivering high-quality synthetic DNA products that optimize R&D and manufacturing workflows. Revenue is generated through partnerships with leading life science investors and the sale of proprietary DNA and resin products. Anjarium's technology enables superior yield, purity, and potency compared to traditional methods, making it a key player in the genetic medicine landscape.
Keywords: synthetic DNA, mRNA production, gene therapy, vector technologies, biotechnology, life sciences, customizable constructs, genetic medicines, R&D optimization, high yield.
Company overview
Anjarium Biosciences AG company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Zurich, Switzerland
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 63.6
Valuation & funding
Anjarium Biosciences AG funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2021 | $61M | $244M | Abingworth · Gimv · Omega Funds · Pfizer Ventures | — |
| SUPPORT PROGRAMOther financing | Dec 2017 | $0 | — | Grow Cluster Wädenswil | — |
Growth signals
Anjarium Biosciences AG website traffic
Latest recorded traffic for Anjarium Biosciences AG is 220 monthly website visits, down 73.2% over the last three months. Anjarium Biosciences AG's team grew 0% over the past year.
Comparisons
Anjarium Biosciences AG compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Anjarium Biosciences AG's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Anjarium Biosciences AG's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Anjarium Biosciences AG has talent and traffic
team presence
In the news
Latest news about Anjarium Biosciences AG
Recent press, funding announcements, and product moves mentioning Anjarium Biosciences AG — open to read from the original sources.
Market sentiment
What the market is saying about Anjarium Biosciences AG
An AI-synthesized read of the highest-engagement posts about Anjarium Biosciences AG on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anjarium Biosciences AG’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.